Norway
GlucoSet, founded in 2011 and headquartered in Norway, is poised to revolutionize the Intensive Care Unit (ICU) environment with its cutting-edge biotechnology solutions. The company operates in the Biotechnology, Health Care, and Medical Devices industries, focusing on addressing critical health challenges in ICUs.
The company's mission, encapsulated by its slogan, "Intensive care monitoring," is to enhance patient outcomes by providing continuous and accurate monitoring of blood glucose levels. With elevated and unstable glucose levels being common and dangerous in ICU patients, GlucoSet's intravascular sensor technology promises to reduce complications, mortality rates, and healthcare costs through precise glucose control.
Recently, the company attracted investment from EIT Health through a Support Program investment dated 01 January 2025. This infusion of capital is expected to accelerate their technology's development and deployment, making GlucoSet an attractive prospect for investors in the med-tech space.
